ORYZON Announces FDA Approval of IND for FRIDA, a Phase Ib Trial with Iadademstat in R/R AML FLT3mut⁺ Patients

Oryzon Genomics, S.A. announced that it has received notification from the US FDA that its Investigational New Drug application (IND) for iadademstat is now approved to initiate a Phase Ib clinical trial in patients with relapsed/refractory AML harboring a FMS-like tyrosine kinase mutation (FLT3mut+ ).